Abridge vs Alan
In-depth comparison — valuation, funding, investors, founders & more
🇺🇸 United States · Shiv Rao
Valuation
$850M
Total Funding
$150M
120 employees
🇫🇷 France · Jean-Charles Samuelian
Valuation
$1.4B
Total Funding
$220M
500-1000 employees
Analyst Summary
Generated from real data · No AI hallucinations
Both Abridge and Alan compete directly in the AI Healthcare space, making this a head-to-head matchup within the same market segment. Abridge is an AI health company founded in 2018 that develops clinical documentation and conversation intelligence tools for healthcare providers. Alan is an AI-powered health insurance platform that combines employer group health insurance products with a digital health companion application, using AI to personalise member health recommendations, streamline claims processing, and provide on-demand access to telehealth and mental health resources.
Alan ($1.4B) is valued slightly higher than Abridge ($850M). On the funding side, Alan has raised $220M in total — $70M more than Abridge's $150M.
Alan has 2 years more market experience, having been founded in 2016 compared to Abridge's 2018 founding. In terms of growth stage, Abridge is at Series B while Alan is at Series D — a meaningful difference for investors evaluating risk and upside.
Abridge operates out of 🇺🇸 United States while Alan is based in 🇫🇷 France, giving each a distinct home-market advantage. On Awaira's 0–100 composite score, Alan leads with a score of 83, reflecting stronger overall fundamentals across valuation, funding, and growth signals.
Metrics Comparison
| Metric | Abridge | Alan |
|---|---|---|
💰Valuation | $850M | $1.4BWINS |
📈Total Funding | $150M | $220MWINS |
📅Founded | 2018WINS | 2016 |
🚀Stage | Series B | Series D |
👥Employees | 120 | 500-1000 |
🌍Country | United States | France |
🏷️Category | AI Healthcare | AI Healthcare |
⭐Awaira Score | 76 | 83WINS |
Key Differences
Valuation gap: Alan is valued 1.6x higher ($1.4B vs $850M)
Funding gap: Alan has raised $70M more ($220M vs $150M)
Market experience: Alan has 2 years more (founded 2016 vs 2018)
Growth stage: Abridge is at Series B vs Alan at Series D
Team size: Abridge has 120 employees vs Alan's 500-1000
Market base: 🇺🇸 Abridge (United States) vs 🇫🇷 Alan (France)
Direct competitors: Both operate in the AI Healthcare market segment
Awaira Score: Alan scores 83/100 vs Abridge's 76/100
Which Should You Choose?
Use these signals to make the right call
Choose Abridge if…
- ✓United States-based for regional compliance or proximity
- ✓Abridge is an AI health company founded in 2018 that develops clinical documentation and conversation intelligence tools for healthcare providers
Choose Alan if…
Top Pick- ✓Higher Awaira Score — 83/100 vs 76/100
- ✓More established by valuation ($1.4B)
- ✓Stronger investor backing — raised $220M
- ✓More market experience — founded in 2016
- ✓France-based for regional compliance or proximity
- ✓Alan is an AI-powered health insurance platform that combines employer group health insurance products with a digital health companion application, using AI to personalise member health recommendations, streamline claims processing, and provide on-demand access to telehealth and mental health resources
Funding History
Abridge raised $150M across 6 rounds. Alan raised $220M across 0 rounds.
Abridge
Series B
Jan 2023
Series B
Jan 2022
Series A
Jun 2021
Lead: Kleiner Perkins
Series A
Jan 2021
Seed
Jan 2019
Seed
Jan 2019
Alan
No public funding data available.
Investor Comparison
No shared investors detected between these two companies.
Unique to Abridge